Skip to Content

Prezcobix Approval History

Prezcobix (darunavir and cobicistat) is a once-daily fixed-dose combination containing a protease inhibitor and a pharmacokinetic enhancer for the treatment of HIV-1 infection.

Development History and FDA Approval Process for Prezcobix

Jan 29, 2015Approval FDA Approves Prezcobix (darunavir and cobicistat) for HIV-1 Infection in Adults
Apr  1, 2014Janssen Submits NDA for a Fixed-Dose Combination of Darunavir with Cobicistat

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.